JP2009501707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501707A5 JP2009501707A5 JP2008520333A JP2008520333A JP2009501707A5 JP 2009501707 A5 JP2009501707 A5 JP 2009501707A5 JP 2008520333 A JP2008520333 A JP 2008520333A JP 2008520333 A JP2008520333 A JP 2008520333A JP 2009501707 A5 JP2009501707 A5 JP 2009501707A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- daunorubicin
- administered
- zoskidal
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69693005P | 2005-07-06 | 2005-07-06 | |
| US11/416,829 US20070010478A1 (en) | 2005-07-06 | 2006-05-03 | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| US11/416,571 US20070010465A1 (en) | 2005-07-06 | 2006-05-03 | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| US11/416,832 US20070010466A1 (en) | 2005-07-06 | 2006-05-03 | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| PCT/US2006/025993 WO2007008490A2 (en) | 2005-07-06 | 2006-06-30 | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009501707A JP2009501707A (ja) | 2009-01-22 |
| JP2009501707A5 true JP2009501707A5 (enExample) | 2009-08-13 |
Family
ID=37637706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008520333A Pending JP2009501707A (ja) | 2005-07-06 | 2006-06-30 | 癌の処置のためのゾスキダル、ダウノルビシン、およびシタラビン |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1898916A4 (enExample) |
| JP (1) | JP2009501707A (enExample) |
| KR (1) | KR20080034151A (enExample) |
| AU (1) | AU2006269492A1 (enExample) |
| CA (1) | CA2614324A1 (enExample) |
| WO (1) | WO2007008490A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2947557T3 (es) * | 2013-09-06 | 2023-08-11 | Vanda Pharmaceuticals Inc | Tratamiento de afecciones mediadas por CYR61 y VEGF |
| US9757385B2 (en) * | 2013-11-27 | 2017-09-12 | Merck Sharp & Dohme Corp. | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
| CN109475542A (zh) * | 2016-07-27 | 2019-03-15 | 弗吉尼亚大学专利基金会 | 用于治疗癌症的组合疗法 |
| WO2023144830A1 (en) | 2022-01-30 | 2023-08-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Zika m protein blockers as anti-zika virus agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002005818A2 (en) * | 2000-07-18 | 2002-01-24 | Eli Lilly And Company | Novel method of use of multidrug resistance modulators |
-
2006
- 2006-06-30 WO PCT/US2006/025993 patent/WO2007008490A2/en not_active Ceased
- 2006-06-30 EP EP06774465A patent/EP1898916A4/en not_active Withdrawn
- 2006-06-30 AU AU2006269492A patent/AU2006269492A1/en not_active Abandoned
- 2006-06-30 KR KR1020087003227A patent/KR20080034151A/ko not_active Withdrawn
- 2006-06-30 JP JP2008520333A patent/JP2009501707A/ja active Pending
- 2006-06-30 CA CA002614324A patent/CA2614324A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020033360A5 (enExample) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2002537332A (ja) | 内臓痛を予防及び治療するためのガバペンチン誘導体 | |
| KR20150050595A (ko) | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 | |
| WO2006014381A3 (en) | Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies | |
| JP2010518164A5 (enExample) | ||
| RU2015141151A (ru) | Идентификация реакции пациентов на введение модулятора рецепторов s1p | |
| Yang et al. | Successful treatment of severe lactic acidosis caused by a suicide attempt with a metformin overdose | |
| CN109689105A (zh) | Fxr激动剂的组合 | |
| Bach et al. | Drugs for pain management in shock wave lithotripsy | |
| Zhu et al. | Electroacupuncture at BL15 attenuates chronic fatigue syndrome by downregulating iNOS/NO signaling in C57BL/6 mice | |
| JP2008517991A5 (enExample) | ||
| JP2009501707A5 (enExample) | ||
| Ryu et al. | Analgesic effects of palonosetron in the intravenous propofol injection | |
| PT1378267E (pt) | Utilização de fluamazenil para se produzir um medicamento para o tratamento da dependência em relação a cocaína | |
| RU2007133435A (ru) | Способ комбинированного лечения и применимые для этого сочетания лекарственных средств | |
| Hirayama et al. | Effects of the addition of low-dose ketamine to propofol anesthesia in the dental procedure for intellectually disabled patients | |
| Jasani et al. | Localised mid‐jejunal volvulus following intussusception and enteroplication in a dog | |
| ATE446309T1 (de) | Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung | |
| RU2337684C1 (ru) | Способ лечения поздних форм нейросифилиса | |
| JP5274071B2 (ja) | 線維筋痛症治療剤 | |
| RU2324480C2 (ru) | Способ профилактики и лечения реактивного панкреатита | |
| JP2005314380A5 (enExample) | ||
| WO2009046580A1 (en) | The application of the combination of insulin or oral hypoglycemic medicine with raceanisodamine hydrochloride, vitamin b12 and nerve growth factor in the preparation of medicine for treating type ii diabetes | |
| Beyan et al. | Bradycardia due to methylprednisolone therapy |